Combining programmed cell death protein-1 (PD-1) inhibitors with chemotherapy (CT) has recently emerged as a promising first-line (1L) treatment to enhance outcomes for patients with advanced or metastatic ESCC who are eligible for initial systemic therapy (11). The gene discussed is PDCD1; the disease is esophageal squamous cell carcinoma.